ASCO-GI: Overall Survival With Erbitux Is Significantly Improved In Patients With KRAS Wild-Type Tumors In CRYSTAL
January 25, 2010 – 7:23 pmMerck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.1 In addition, the final results from this study included an analysis of the predictive value of BRAF status on Erbitux efficacy – one of the first to be based on a large subgroup (n=59) of a prospective, randomized study in the 1st-line setting…
Related Info :
Tags: ASCO, ASCOGI, Cancer Patients, Cetuximab, Chemotherapy, Colorectal, Colorectal Cancer, CRYSTAL, Darmstadt Germany, Efficacy, Erbitux, Improved, KRAS, Merck, Merck Kgaa, Merck Kgaa Darmstadt, Overall, Patients, Predictive Value, Prospective Randomized Study, Regimen, Significantly, Subgroup, survival, Tumors, WildType
